EMA committee recommends market withdrawal of obesity drug

Obesity drug amfepramone is not used as it was intended and can cause serious side effects, which is why the European Medicines Agency’s risk assessment committee recommends market authorizations be withdrawn.

Photo: Rob Acket/EMA

Studies from both Denmark and Germany have made the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) recommend that obesity drugs containing amfepramone be withdrawn from the market, the committee reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs